Objective: To determine whether the activation of innate immune responses, which can be elicited by pathogenic and endogenous triggers, is associated with the presence of Epstein-Barr virus (EBV) infection in the multiple sclerosis (MS) brain.
Infectious agents are plausible candidates for triggering and perpetuating multiple sclerosis (MS) in genetically susceptible subjects. The strength of its associations renders Epstein-Barr virus (EBV), a herpesvirus with a population prevalence Ͼ90%, the outstanding candidate. A history of symptomatic infectious mononucleosis increases the MS risk more than twofold 3 and elevated serum antibody titers to EBV nuclear antigen 1 (EBNA-1) precede the onset of MS, and are associated with MRI activity in established disease. 4, 5 Furthermore, EBV infection was found to be a characteristic feature of the MS brain 6 ; however, these findings were countered by other studies. [7] [8] [9] EBV infects predominantly B lymphocytes and persists in the blood in rare memory B cells. The gold standard for detecting EBV in tissue is in situ hybridization for the EBERs, 2 small EBV-RNAs (EBER1 and EBER2), abundant in EBV-infected cells (10 6 -10 7 copies/infected cell nucleus) 10 with immunomodulatory effects upon secretion and TLR3 ligation on neighboring cells. 11 Our hypothesis is that active MS lesions carry an IFN␣ signature, which can be elicited by viral stimuli. We propose that innate activation in these areas, driven or maintained by EBV-encoded RNAs, leads to an antiviral state that contributes to neuroinflammation.
METHODS Standard protocol approvals, registration, and patient consents. Postmortem paraffin brain and control tissues were obtained from the Thomas-Willis-Oxford Brain Collection, Oxford, with informed consent and Ethics Committee approval (REC: 08/H0304/7).
Tissue specimens. For all MS brains studied, the clinical diagnosis had been made during life and confirmed at autopsy. Brains from patients with cancer and other neurologic and neuroinflammatory diseases were used as controls (table e-1 on the Neurology ® Web site at www.neurology.org). To characterize white matter lesions, Luxol fast blue (LFB), anti-human leukocyte antigen (HLA) class II (macrophages/microglia), and hematoxylin & eosin (H&E) staining was performed to identify the centers and borders of lesions and their activity, and areas of hypercellularity (inflammatory cell infiltration) and hypocellularity (loss of parenchymal cells in inactive lesions). Lesions were classified into 3 groups: 1) acute lesions, rich in dense lymphocytic infiltrates with numerous B cells and macrophages (containing LFB); 2) chronic active lesions, characterized by hypercellular active borders staining strongly for LFB in macrophages and hypocellular demyelinated centers, with very low densities of LFB-negative macrophages; 3) inactive lesions, characterized by demyelination and marked hypocellularity (reflecting loss of parenchymal cells) and only limited numbers of LFB-negative inflammatory cells. Case 13 is a stroke case with cause of death noted as cerebral hemorrhage with some B-cell infiltration, whereas case 12, without B-cell infiltration, died of pulmonary embolism.
Immunohistochemistry for IFN␣, gp350, LMP-1, and plasmacytoid-dendritic-cell markers. Paraffin sections (6 m) used in this study were deparaffinized and antigens unmasked as described previously. 12 Sections were blocked with 10% fetal calf serum (FCS) followed by staining with sheep polyclonal anti-IFN␣ antibody at 1/1,000 dilution in 10% FCS. This antibody was raised against lymphoblastoid IFN␣ and is thus broadly cross-reactive with IFN␣ subtypes. 13 Antisheep immunoglobulin G (IgG) antibody (Vector, UK) was used as secondary antibody followed by avidin-biotin peroxidase complex (ABC kit, Vector, UK) and detected with diaminobenzidine substrate (DAKO, UK). B cells in MS lesions were stained with anti-CD79␣, which is part of the B cell receptor complex (JCB117 clone, donated by Prof. Margaret Jones), 14 and developed with Dako Real Envision Detection System as described previously.
12 LMP-1 and gp350/220 were detected with the mouse IgG1 monoclonal antibodies (mAb) OT21C (LMP-1; 1/500) and OT6 (gp350; 1/2,000), both of mouse origin (IgG1), in phosphate-buffered saline (PBS) containing 1% bovine serum albumin. 15 Binding was visualized with labeled polymer HRP (peroxidase-labeled polymer conjugated to goat antimouse and goat antirabbit Igs in Tris-HCl buffer, Dako, UK) for 30 minutes followed by DAB as above. All sections were counterstained with hematoxylin. pDCs staining was done as described previously using BDCA2 clone 124B3.13 (1/50) (Dendritics, France) 16, 17 ; CD2ap, clone B-4 (1/1,000; Santa Cruz Biotechnology, USA) 18 ; and CD123, clone 7G3 (1/50; BD Biosciences, USA).
Immunofluorescence staining. For double-labeling, IFN␣ staining was performed as described above, followed by biotinantisheep Ig (Vector, UK), visualized with conjugated streptavidin alexa-488 (Invitrogen, Paisley, UK). Slides were incubated overnight with second primary antibodies: rat anti-major histocompatibility complex class II (1/200 dilution; Dako, UK), rat anti-CD3 (1/100; Serotec UK), mouse anti-CD19 (1/50; Serotec, UK), rabbit anti-GFAP (1/1,000; Dako, UK), or mouse anti-protein lipid protein (PLP) (1/200; Serotec). Appropriate secondary antibodies included Alexa 568 anti-rat Ig (1/200; Invitrogen, UK), Alexa 568 antimouse Ig (1/200), and Alexa Fluor 568-antirabbit (1/200) for 3 hours. As negative controls for each second layer, primary antibodies were omitted. No staining was seen in these sections.
In situ hybridization for the detection of EBERs in brain tissue. The EBER-in situ hybridization (ISH) was carried out essentially as previously described in detail. 10, 19 Two antisense oligonucleotides (30 nucleotides each) corresponding to positions 91-120 and 82-111 of EBER 1 and EBER 2, respectively, were synthesized (Sigma, UK) and end-labeled by tailing with digoxigenin-dUTP using a commercially available kit (Roche Diagnostics, UK), following the manufacturer's instructions. Briefly, 6-m sections on sialinized slides were dewaxed and digested with 100 g/mL proteinase K for 15 minutes in a 37°C incubator. Sections were subsequently washed in water and dehydrated in ethanol. Sections were incubated with hybridization buffer containing 100 ng/mL of EBER-1/EBER-2 probe. The EBER probes and target nucleic acid were denatured using microwave irradiation followed by hybridization overnight at 42°C in a hot air oven. After high-stringency washes in 0.1ϫ SSC at 55°C, hybridized probes were detected using mouse antidigoxin mAb (1/5,000; Sigma, UK) followed by the avidinbiotin complex peroxidase technique (ABC-Elite kit, Vector Laboratories, UK) and DAB as the chromogenic substrate. We examined all lesions blindly, i.e., without knowledge of the other results or the histologic status of the MS lesions. A negative control (using PBS instead of EBER probes) was included with each sample. Hodgkin lymphoma or post-transplant lymphoma (PTLD) sections were included as positive controls with each batch. In our previous studies, 10, 19 negative controls included treatment of sections with RNase prior to hybridization with EBER probes and using random probes of the same size and GC content to EBER probes. Our findings consistently showed that our EBER probes were highly specific, giving positive signals only in samples containing EBV.
EBER-encoding plasmids. Plasmids encoding EBER1
or EBER2 were prepared by cloning PCR-amplified B95-8 EBV EBER1 or EBER2 DNA digested with BglII and HindIII into pSUPER (OligoEngine Ltd., Seattle) between the BglII and HindIII sites. EBER plasmids were calibrated and found to give transient expression similar to that found in EBV-infected cells as determined by Northern blotting and flow cytometric staining for EBER-RNA.
Primers were as follows: EBER1 Bgl II CCAGATCTCCAGGACCTACGCTGCCCT EBER1 Hind III CCAAGCTTGGATGCATAAATCCTAA EBER 2 Bgl II CCAGATCTCCAGGACAGCCGTTGCCCT EBER 2 Hind III CCAAGCTTGGGTGCAAAACTAGCCA
Transfection of EBER-encoding plasmids into HEK293/TLR3 cells. HEK293 cells stably transfected with
TLR3 (Invivogen, UK) were cultured in Dulbecco modified Eagle medium supplemented with 10% FCS, penicillin (100 U/mL), and streptomycin (100 g/mL) and 5 g/mL of blasticidin for selection. Plasmids encoding EBER1, EBER2, or empty vector were used to transfect HEK293/TLR3 cells, seeded at 7.5 ϫ 10 4 /mL in 24-well plates. Cells were 80% confluent at the time of transfection with Fugene HD (Roche) at a ratio of 0.75 g Fugene: 0.5 g of DNA. A GFP-encoding plasmid (Lonza, UK) was cotransfected as a control and comparable transfection efficiency checked by microscopy. As positive controls, cells were transfected with polyIC at the same ratio. Transfections were performed in duplicate and supernatants were collected after 24 hours of culture; their IFN␣ content was determined with a human IFN␣ multisubtype ELISA kit (PBL Interferon Source, UK).
Data acquisition and statistical analysis. The numbers of
IFN␣ϩ cells/mm 2 were counted in 3 100ϫ parenchymal fields per lesion with a total area ϭ 1.735 ϫ 10 6 m 2 using ImageJ (NIH). Digital images of tissue sections were made with Olympus light microscope BX41 and Zeiss camera (Zeiss, Thornwood, NY). To investigate IFN␣ protein colocalization, multiple images were acquired using a confocal microscope (BioRad, Hercules, CA). We performed semiquantification by counting of EBERϩ, LMP-1ϩ, and gp350ϩ cells in perivascular cuffs and parenchyma of MS lesions with different activity and observations were confirmed blindly by a second pathologist. Statistical analysis was performed using analysis of variance (SPSS, IBM).
RESULTS IFN␣ is expressed in active areas of MS
lesions by HLA class II-expressing cells. To investigate the potential role of innate immunity in the pathogenesis of MS, we studied the expression of IFN␣ within white matter of MS lesions with different disease activity. Large numbers of cells labeling very strongly for IFN␣ϩ were observed consistently in all the acute lesions ( figure 1A ) and borders of chronic active MS lesions (figure 1B). In contrast, we found ϳ5 times fewer IFN␣ϩ cells in the inactive centers of chronic active MS lesions ( figure 1C ) and in inactive MS lesions ( figure 1D ). IFN␣ϩ cells were rare in normal-appearing white matter ( figure 1E ) and normal control brain tissue ( figure 1F ). These differences and their significance are quantified in figure 1J . The IFN␣-producing cells were consistently HLA class IIϩ in MS lesions, and showed the morphology of macrophages/microglia (figure 1, G-I). In sharp contrast, B cells (CD19ϩ), T cells (CD3ϩ), astrocytes (GFAPϩ), and oligodendrocytes (PLPϩ) showed no detectable immunoreactivity for IFN␣ (figure e-1A).
Detection of EBV RNAs and proteins in active MS
lesions that show IFN␣ signatures. We next checked for the presence of EBV-infected cells in active MS lesions overexpressing IFN␣ by EBER-ISH. This approach, therefore, represents a preselection strategy to identify active MS lesions, and increase the possibility of finding EBERϩ cells. Positive controls included Hodgkin-, post-transplant-, and AIDSassociated CNS lymphomas and oral hairy leukoplakia (OHL), all of which were known to be EBVϩ. Our disease controls were 2 cases of stroke and 1 each with subacute sclerosing panencephalitis (SSPE) and herpes simplex encephalitis (HSE), and there were 2 healthy control brains (table e-1).
We observed EBERϩ cells in white matter areas of all the active MS lesions (figure 2A), including active areas of chronic-active MS lesions (figure 4A and figure e-2, C). In all cases, the EBER signal was nuclear, as in the Hodgkin lymphoma control ( figure  2D ). We We next checked for EBV-encoded markers for its latency program II/III (LMP-1) and lytic replication (gp350). The LMP-1 antibody stained cytoplasm and surface membranes in the Hodgkin lymphoma (figure 2E) as previously described. 20 We observed cross-reactivity of LMP-1 with ␣-synuclein in brain tissue, which led to strong background staining, particularly in the cortex rather than white matter areas. 21 We detected gp350ϩ cells in OHL tissue (figure 2F). We only found the occasional LMP-1ϩ and gp350ϩ cell in EBERϩ active MS lesions ( figure 2, B and C) . The results of this semiquantification are shown in table e-1. We also stained consecutive sections for EBERs and IFN␣. Indeed, areas of acute MS lesions consistently exhibited a dual IFN␣/EBER signature (figure 3, A and B). EBERϩ and IFN␣ϩ cells were found in perivascular areas, however, IFN␣ϩ cells were also promi- 
Figure 2 Epstein-Barr virus (EBV) infection is found in active multiple sclerosis (MS) lesions by in situ hybridization

Is cerebral expression of EBERs restricted to MS?
We next studied brains affected by a variety of other disorders. EBERϩ cells were detected in perivascular areas in HIV-associated CNS lymphoma (figure 4B). Stroke is another neurologic disease, where inflammation appears to play an important early role in pathogenesis. 22 Interestingly, we detected EBERϩ cells in 2 cases of stroke ( figure 4C and figure e-2, E) but not in the white matter of healthy control brains ( figure 4D) . The EBERϩ cells were dispersedly located all over the inflammatory area (both perivascular and in the parenchyma). Evidently, EBERϩ cells can be found in other inflammatory conditions such as stroke, which raises interesting questions about their contribution to neuroinflammation in general.
EBERs elicit IFN␣ production in TLR3-expressing HEK cell cultures. Finally, we tested whether EBERs could elicit IFN␣ production and thus contribute to neuroinflammation in the CNS. EBERs form double-stranded (ds) RNA-like molecules with stemloop structures. 23 Virally encoded dsRNAs are one of the proximal inducers of type I IFN production, and their effects can be mimicked by treatment of uninfected cells with the synthetic dsRNA, poly(I): poly(C) (polyIC). 24 HEK cells, stably expressing TLR3, were supertransfected with polyIC, which induced significant IFN␣ production (figure 5). Production of IFN␣ also increased significantly when these cells were transfected instead with either EBER1 or EBER2 expression plasmids. Thus even latent EBV infection can trigger IFN␣ production observed in active MS lesions, and therefore contribute to the neuroinflammation. DISCUSSION The MS brain shows characteristic inflammation that targets myelin sheaths and leads to focal destruction and demyelinated plaques in the white matter. Analysis of white matter areas revealed overexpression of the proinflammatory cytokine IFN␣ in active MS lesions. Notably, we found EBERϩ cells in areas of IFN␣ overexpression. Furthermore, the occasional LMP-1ϩ and gp350ϩ cells were also present in EBERϩ MS lesions. Whereas we detected no signs of EBV infection in white matter areas of SSPE, HSE, and control brains, EBERϩ cells were also present in CNS lymphoma and stroke. We also showed that EBERs can elicit IFN␣ production by TLR3ϩ HEK cells, and can thus contribute to the inflammation in active MS lesions. Together with the overexpression of IFN␣ that we found there too, these findings imply activation of innate immune responses associated with the hitherto unre- ported EBV infection, consistent with its proposed involvement in MS pathogenesis. Our findings suggest that latent EBV infection may contribute significantly to neuroinflammation in patients with MS and possible others, too. Production of IFN␣ is seen during many different systemic virus infections, e.g., EBV, 25 Sendai, 26 and measles viruses. 27 However, there are endogenous stimuli too, as in systemic lupus erythematosus (SLE) 28 and Aicardi-Goutières syndrome. 29 Several CNS disorders such as encephalitis 30 and neuropsychiatric lupus 28 have been linked to dysregulation of IFN␣ responses. We found HLA class IIϩ cells with the morphology of microglia and macrophages expressed IFN␣ in active MS lesions in line with previous study. 31 The presence of plasmacytoid dendritic cells (pDCs) was assessed with 3 pDCs markers (BDCA-2, CD123, CD2ap); pDCs were not detected in active MS lesions in contrast to previous findings 32 (figure e-1B). Though the possible roles of viruses in the pathogenesis of MS have been discussed for many years, [33] [34] [35] there are conflicting recent reports on EBV infection in the MS brain. 6 -9 Our findings are in line with previous reports, which describe the presence of EBERϩ cells in the MS lesions 6 and the observation that active EBV infection is not a characteristic feature of the MS brain. [7] [8] [9] However, our study included a novel preselection strategy and focused only on white matter MS lesions rather than meningeal areas. We believe that there are 2 primary reasons for the discrepancies in previous reports: the sensitivity and specificity of the methodology and the clinical material used. Techniques such as PCR, albeit very sensitive, are dependent on the quality of the extracted DNA, which is generally very poor from formalinfixed tissues and amplification of larger fragments of EBV (Ͼ300 bp) is not consistently possible. 36 In this context, using EBER-ISH is highly favored. However, during the establishment of the EBER-ISH methodology, we have identified that factors such as tissue digestion, probe design, labeling of EBER probes, amount of probe used, microwave heating prior to overnight hybridization, and the stringency washes posthybridization influenced its sensitivity and specificity. 10 Our probe targets EBER1 and EBER2 in contrast to all the other studies. 6 -9 With our optimized protocol, we have consistently been able to detect as little as a few EBV-infected lymphocytes in entire sections. 37 As we found EBERϩ cells not only in white matter areas of these active MS lesions but also CNS lymphoma and 2 cases of stroke, we conclude that the presence of EBV may not be unique to the MS brain in contrast to previous findings. 6 Indeed, some
EBERϩ cells may well be included in the inflammatory infiltrate, attracted by locally produced chemokines and cytokines. We did not find EBERϩ cells in our SSPE and HSE cases. The inflammatory infiltrate may differ in SSPE and HSE. Alternatively these cases may not yet be infected with EBV, as in the teenage SSPE case. Our data addressing a potential mechanism of action, e.g., the role of EBERs in eliciting IFN␣ production, were supported by recent findings, which showed active secretion of EBERs and binding to extracellular TLR3 on dendritic cells, which triggered type I IFN production. 11 More recently, expression of EBER1 in lymphoblastoid cell lines was found to regulate IFN␣6, ␣5, and ␣4 genes. 38 In addition, binding of EBERs to cytosolic "receptor" retinoic acid inducible gene 1 (RIG-I) also induced type-I IFN production. 39, 40 Future studies should include more suitable control cases as this will be crucial to understand the role of EBV in MS. Further characterization of EBERϩ cells is also warranted as not all cells have the morphology of B cells, which is technically extremely difficult given the few EBV-infected cells and problems in combining immunohistochemistry with in situ hybridization without compromising sensitivity and specificity.
Our study indicates that EBV may be more subtle than we anticipated as active EBV infection is not a characteristic feature of the MS brain. Perhaps that is not too surprising as EBV is a persistent virus with the aim to coexist rather than eradicate the host. Thus our study casts new light on mechanistic interactions of viral RNAs and innate immune activation in the CNS, and may highlight the propensity of latent viral infections to contribute to neuroinflammation in the CNS, not only in MS but also in other neuroinflammatory diseases.
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